Hims Hers Health is trading 10.4% up at $30.65 as investors continue to buy the dip following last week’s sharp selloff triggered by an FTC health data privacy complaint.
- The move extends Friday’s rebound, with traders reassessing regulatory risks associated with the July 29 FTC filing.
- Broader market gains are providing additional tailwinds, supporting positive sentiment toward growth-oriented and telehealth stocks.